Scientist, Division of Virus Research and Therapeutics, CSIR-Central Drug Research Institute (CDRI), Lucknow
Do SARS-CoV-2 antibodies enhance dengue virus pathogenesis?
Host: R. Sonti
Host: R. V. Sonti
People living in tropical areas are dealing with both the COVID-19 pandemic and the most common endemic disease, such as dengue. COVID-19 and dengue co-epidemics may pose a daunting challenge to health-care systems in low- and middle-income countries. In this presentation, I will discuss about our initial data that SARS-CoV-2 immunity particularly directed to Spike (S) and Nucleocapsid (N) proteins cross-reacts with DENV structural proteins. Moreover, these antibodies did not neutralize DENVs in vitro but may have enhancement potential to cause severe dengue disease in vivo.
Hundreds of videos, tens of playlists providing free scientific content worldwide